Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Imab save search
Global Bispecific Antibody Market Clinical Trials Insight Report to 2029: 12 Bispecific Antibodies Generated Revenue of Over US$ 8.5 Billion in 2023
Published: 2024-03-13 (Crawled : 03:00) - prnewswire.com
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: 3.28%
H: 2.65%
C: -2.65%
report antibody revenue trials global market
Embattled Researchers See Path Forward for Anti-CD47 Cancer Drugs
Published: 2023-10-30 (Crawled : 05:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: 3.28%
H: 5.56%
C: 2.38%
cd47 cancer
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
Published: 2023-09-27 (Crawled : 15:30) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -2.38%
axes trial
ALX Oncology Axes Two CD47 Programs on Disappointing Results
Published: 2023-08-11 (Crawled : 23:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -1.57%
H: 3.39%
C: 1.2%
cd47 axes results
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Published: 2023-06-20 (Crawled : 12:00) - globenewswire.com
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
|
| O: 1.81%
H: 2.0%
C: -4.02%
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -0.33%
H: 6.72%
C: 5.57%
positive ongoing pharmaceuticals trial response results
Global CD276 Antibody Clinical Trials & Markets Report 2023: Potential $1 Billion Market by 2028, 30 Drugs in Trial, Orphan & Priority Status Review, Insight on 25 Companies
Published: 2023-03-31 (Crawled : 11:00) - prnewswire.com
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -3.41%
H: 4.71%
C: 1.76%
cd276 companies report antibody trials global potential market
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
Published: 2022-12-14 (Crawled : 18:00) - biospace.com/
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
|
| O: 14.5%
H: 7.33%
C: -14.0%
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -2.89%
H: 6.5%
C: 4.07%
ongoing pharmaceuticals trial response positive results
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: 0.17%
H: 0.68%
C: -5.57%
cd47 antibody presentation phase 2
Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab
Published: 2022-08-17 (Crawled : 14:00) - biospace.com/
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: -0.79%
H: 0.95%
C: 0.01%
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -4.39%
H: 0.52%
C: -10.37%
aml trial cancer
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
Published: 2022-07-22 (Crawled : 12:20) - prnewswire.com
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -0.09%
H: 0.28%
C: -5.3%
antibody trial china phase 1
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
Published: 2022-06-14 (Crawled : 10:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -3.71%
H: 0.0%
C: 0.0%
tj101 trial growth phase 3
Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer
Published: 2022-06-07 (Crawled : 09:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -7.1%
H: 11.86%
C: 10.15%
trial results cancer negative breast cancer topline phase 2b
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
Published: 2022-05-31 (Crawled : 21:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: 4.47%
H: 9.37%
C: 0.69%
treatment trial growth hormone
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
Published: 2022-05-19 (Crawled : 19:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -0.66%
H: 5.72%
C: 1.84%
cd73 report antibody phase 2
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -8.6%
H: 5.62%
C: 2.83%
phase 2 solid tumors trial china
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
Published: 2022-01-12 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
phase 2
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
MGNX | $16.12 -3.36% -3.47% 950K
|
Health Technology
|
| O: -0.75%
H: 1.28%
C: -2.84%
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -0.49%
H: 2.25%
C: -0.79%
phase 2 solid tumors trial approval china
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Published: 2021-12-15 (Crawled : 15:30) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -11.41%
H: 8.08%
C: 7.32%
solid tumors trial approval phase 1 china antibody phase 2
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
Published: 2021-12-03 (Crawled : 13:30) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: -5.2%
H: 0.0%
C: 0.0%
phase 2 solid tumors trial
Nasal Vaccine Starts Trial to Protect Against Alzheimer's
Published: 2021-11-16 (Crawled : 18:00) - biospace.com/
IMAB | $1.81 1.12% 1.1% 390K
|
Health Technology
|
| O: 3.64%
H: 0.0%
C: 0.0%
alzheimer vaccine trial alzheimer’s alzheimer's
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.